The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Biogen Inc. BIIB shares rallied 7% in the last trading session to close at $216.03. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

This could be a key move for future growth.

Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed ...

Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company’s market value has increased by approximately $3.3 billion over ...

Although the broader healthcare sector has witnessed significant turbulence throughout this year, some notable players have been making positive waves. One of these names is Biogen (NASDAQ: BIIB), a ...

The Italian Competition Authority on Wednesday announced an investigation into Biogen (BIIB) over alleged abuse of market dominance to sell a multiple sclerosis medication in Italy, rivaling a ...

Biogen BIIB and Amgen AMGN are two of the biggest biotech companies in the world. Amgen has a strong presence in the oncology ...

As of October 29, 2025, the average one-year price target for Biogen is $175.03/share. The forecasts range from a low of $119.18 to a high of $273.00. The average price target represents an increase ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...